Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 7 Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2 Refractory or Relapsed Solid Tumors 1 Prostatic Neoplasms, Castration-Resistant 1 Non-metastatic Castration-resistant Prostate Cancer 1 Metastatic Castration-resistant Prostate Neoplasms 1 Metastatic Castration-resistant Prostate Cancer 1 Bulbo-Spinal Atrophy, X-Linked 1 Biochemically Recurrent Prostate Cancer 1 Adenocarcinoma 1

Interventions

enzalutamide 1 darolutamide 1 abiraterone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Bulbo-Spinal Atrophy, X-Linked × darolutamide × 30 days × Clear all

NCT07190300 2026-06-03

TulmiSTAR-02

Novartis

Phase 1/2 Recruiting

Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon ⚡